{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unfractionated+Heparin&page=2",
    "query": {
      "condition": "Unfractionated Heparin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unfractionated+Heparin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T13:52:15.028Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04818151",
      "title": "Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolic Disease",
        "Kidney Failure, Chronic"
      ],
      "interventions": [
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14914,
      "start_date": "2021-01-01",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-26",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04818151"
    },
    {
      "nct_id": "NCT00116012",
      "title": "Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "rNAPc2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ARCA Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 300,
      "start_date": "2005-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-11-29",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116012"
    },
    {
      "nct_id": "NCT03894904",
      "title": "Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pediatrics",
        "Anesthesia",
        "Vasospasm"
      ],
      "interventions": [
        {
          "name": "Papaverine",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        },
        {
          "name": "Rescue papaverine, as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 100,
      "start_date": "2019-04-01",
      "completion_date": "2020-10-10",
      "has_results": true,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894904"
    },
    {
      "nct_id": "NCT00657228",
      "title": "Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anaphylaxis"
      ],
      "interventions": [
        {
          "name": "Intravenous heparin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri, Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-12",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 2,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657228"
    },
    {
      "nct_id": "NCT00587444",
      "title": "Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Heparin",
          "type": "DRUG"
        },
        {
          "name": "HH or high heparin",
          "type": "DRUG"
        },
        {
          "name": "heparin concentration HC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 270,
      "start_date": "2001-06",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2009-10-15",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587444"
    },
    {
      "nct_id": "NCT00201903",
      "title": "The Roles of Tissue Factor in Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolism",
        "Brain Tumors"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ontario Clinical Oncology Group (OCOG)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-01",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2017-04-06",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201903"
    },
    {
      "nct_id": "NCT00252005",
      "title": "Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Deep-Vein Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 520,
      "start_date": "2005-11",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 5,
      "location_summary": "Albuquerque, New Mexico • Chapel Hill, North Carolina • San Antonio, Texas + 2 more",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fredericksburg",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00252005"
    },
    {
      "nct_id": "NCT04351438",
      "title": "Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Therapeutic Plasma Exchange",
        "Anticoagulant Therapy"
      ],
      "interventions": [
        {
          "name": "Active Comparator: centrifuge TPE with citrate",
          "type": "DEVICE"
        },
        {
          "name": "Active Comparator: Filter TPE with heparin",
          "type": "DEVICE"
        },
        {
          "name": "Active comparator: Filter TPE with citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "0 Years to 24 Years"
      },
      "enrollment_count": 108,
      "start_date": "2012-01-01",
      "completion_date": "2024-02-04",
      "has_results": false,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351438"
    },
    {
      "nct_id": "NCT05325346",
      "title": "A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heparin-induced Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "VLX-1005",
          "type": "DRUG"
        },
        {
          "name": "Argatroban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veralox Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-03-07",
      "completion_date": "2022-04-14",
      "has_results": false,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05325346"
    },
    {
      "nct_id": "NCT01598883",
      "title": "Understanding \"Heparin Resistance\" in Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiopulmonary Bypass",
        "Altered Heparin Response"
      ],
      "interventions": [
        {
          "name": "Heparin",
          "type": "DRUG"
        },
        {
          "name": "ATryn",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 504,
      "start_date": "2012-06",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-14",
      "last_synced_at": "2026-09-26T13:52:15.028Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01598883"
    }
  ]
}